S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in

STAAR Surgical Stock Forecast, Price & News

+3.81 (+3.43 %)
(As of 02/24/2021 12:00 AM ET)
Today's Range
Now: $114.86
50-Day Range
MA: $103.87
52-Week Range
Now: $114.86
Volume530,899 shs
Average Volume954,807 shs
Market Capitalization$5.35 billion
P/E Ratio604.56
Dividend YieldN/A
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers intraocular lenses (IOLs), including collamer material and silicone foldable IOLs, and nanoFLEX IOL that produces a clearer image, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision centers, surgical centers, hospitals, government facilities, and distributors primarily under the STAAR, EVO Visian ICL, Evolution in Visual Freedom, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, and Afinity trademarks. The company sells its products directly through its sales representatives in the United States, Japan, Spain, Germany, Canada, the United Kingdom, and Singapore, as well as through independent distributors in China, Korea, India, and internationally. STAAR Surgical Company was founded in 1982 and is based in Lake Forest, California.
STAAR Surgical logo

Industry, Sector and Symbol

Industry Ophthalmic goods
Sub-IndustryHealth Care Supplies
Current SymbolNASDAQ:STAA
Year FoundedN/A



Sales & Book Value

Annual Sales$150.18 million
Cash Flow$0.74 per share
Book Value$3.59 per share


Net Income$14.05 million


Market Cap$5.35 billion
Next Earnings Date5/4/2021 (Estimated)


Overall MarketRank

1.38 out of 5 stars

Medical Sector

574th out of 1,958 stocks

Ophthalmic Goods Industry

3rd out of 8 stocks

Analyst Opinion: 1.3Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
+3.81 (+3.43 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive STAA News and Ratings via Email

Sign-up to receive the latest news and ratings for STAA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

STAAR Surgical (NASDAQ:STAA) Frequently Asked Questions

Is STAAR Surgical a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STAAR Surgical stock.
View analyst ratings for STAAR Surgical
or view top-rated stocks.

What stocks does MarketBeat like better than STAAR Surgical?

Wall Street analysts have given STAAR Surgical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but STAAR Surgical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting STAAR Surgical?

STAAR Surgical saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 1,820,000 shares, a decline of 20.5% from the December 31st total of 2,290,000 shares. Based on an average daily trading volume, of 560,200 shares, the days-to-cover ratio is currently 3.2 days.
View STAAR Surgical's Short Interest

When is STAAR Surgical's next earnings date?

STAAR Surgical is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for STAAR Surgical

How were STAAR Surgical's earnings last quarter?

STAAR Surgical (NASDAQ:STAA) posted its earnings results on Monday, November, 9th. The medical instruments supplier reported $0.14 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.09 by $0.05. The medical instruments supplier had revenue of $47.10 million for the quarter, compared to the consensus estimate of $42.99 million. STAAR Surgical had a net margin of 5.73% and a trailing twelve-month return on equity of 8.99%. STAAR Surgical's revenue was up 20.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.05 EPS.
View STAAR Surgical's earnings history

How has STAAR Surgical's stock been impacted by COVID-19?

STAAR Surgical's stock was trading at $28.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, STAA stock has increased by 310.1% and is now trading at $114.86.
View which stocks have been most impacted by COVID-19

What price target have analysts set for STAA?

6 analysts have issued 1 year price objectives for STAAR Surgical's shares. Their forecasts range from $41.00 to $84.00. On average, they anticipate STAAR Surgical's share price to reach $61.17 in the next twelve months. This suggests that the stock has a possible downside of 46.7%.
View analysts' price targets for STAAR Surgical
or view top-rated stocks among Wall Street analysts.

Who are STAAR Surgical's key executives?

STAAR Surgical's management team includes the following people:
  • Ms. Caren L. Mason, CEO, Pres & Director (Age 67, Pay $1.19M)
  • Dr. Keith Holliday, Chief Technology Officer (Age 58, Pay $597.39k)
  • Mr. Hans-Martin Blickensdoerfer, Sr. VP of Commercial Operations and Director of Markets - Europe & China (Age 56, Pay $561.19k)
  • Dr. Scott D. Barnes M.D., Chief Medical Officer (Age 59, Pay $681.32k)
  • Mr. Patrick F. Williams, Chief Financial Officer (Age 48)
  • Mr. Graydon C. Hansen, Sr. VP of Global Operations (Age 62)
  • Mr. Brian Moore, VP of Investor, Media Relations & Corp. Devel.
  • Mr. Samuel J. Gesten, Chief Legal Officer & Corp. Sec. (Age 59)
  • Mr. William Goodmen, VP of Global HR (Age 66)
  • Mr. James Francese, Sr. VP of Commercial Operations - North America & APAC (Age 57)

What is Caren Mason's approval rating as STAAR Surgical's CEO?

6 employees have rated STAAR Surgical CEO Caren Mason on Glassdoor.com. Caren Mason has an approval rating of 68% among STAAR Surgical's employees.

Who are some of STAAR Surgical's key competitors?

What other stocks do shareholders of STAAR Surgical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STAAR Surgical investors own include Tesla (TSLA), NVIDIA (NVDA), PayPal (PYPL), The Walt Disney (DIS), CrowdStrike (CRWD), DocuSign (DOCU), Shopify (SHOP), The Trade Desk (TTD), Teladoc Health (TDOC) and Roku (ROKU).

What is STAAR Surgical's stock symbol?

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

Who are STAAR Surgical's major shareholders?

STAAR Surgical's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.62%), Baillie Gifford & Co. (5.09%), Morgan Stanley (1.36%), Northern Trust Corp (1.23%), Artisan Partners Limited Partnership (1.08%) and Defender Capital LLC. (0.96%). Company insiders that own STAAR Surgical stock include Broadwood Partners, LP, Caren L Mason, Deborah J Andrews, Graydon C Hansen, Hans-Martin Blickensdoerfer, Jon K Hayashida, Keith Holliday, Samuel J Gesten and Scott D Barnes.
View institutional ownership trends for STAAR Surgical

Which major investors are selling STAAR Surgical stock?

STAA stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Defender Capital LLC., Pura Vida Investments LLC, Royce & Associates LP, Acuitas Investments LLC, Nuveen Asset Management LLC, RE Advisers Corp, and TCW Group Inc.. Company insiders that have sold STAAR Surgical company stock in the last year include Broadwood Partners, LP, Hans-Martin Blickensdoerfer, Jon K Hayashida, Keith Holliday, and Samuel J Gesten.
View insider buying and selling activity for STAAR Surgical
or view top insider-selling stocks.

Which major investors are buying STAAR Surgical stock?

STAA stock was purchased by a variety of institutional investors in the last quarter, including APEIRON CAPITAL Ltd, Canada Pension Plan Investment Board, BlackRock Inc., Morgan Stanley, JPMorgan Chase & Co., KAMES CAPITAL plc, Price T Rowe Associates Inc. MD, and Boyu Capital Investment Management Co. Limited.
View insider buying and selling activity for STAAR Surgical
or or view top insider-buying stocks.

How do I buy shares of STAAR Surgical?

Shares of STAA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is STAAR Surgical's stock price today?

One share of STAA stock can currently be purchased for approximately $114.86.

How much money does STAAR Surgical make?

STAAR Surgical has a market capitalization of $5.35 billion and generates $150.18 million in revenue each year. The medical instruments supplier earns $14.05 million in net income (profit) each year or $0.46 on an earnings per share basis.

How many employees does STAAR Surgical have?

STAAR Surgical employs 550 workers across the globe.

What is STAAR Surgical's official website?

The official website for STAAR Surgical is www.staar.com.

Where are STAAR Surgical's headquarters?

STAAR Surgical is headquartered at 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630.

How can I contact STAAR Surgical?

STAAR Surgical's mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected]

This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.